SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

by Ysios Capital

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...

Read more

Health Tech VC firm Nina Capital, focused on Life Sciences, Closes Oversubscribed Second Fund and Announces its First Four Investments

by Professional Newco

Nina Capital, an emerging specialist venture capital firm, today announced its second fund, started last fall, eclipsed its target size of EUR40 million in just four months. The fund will be used to c...

Read more

40 biotech participan en Health BioMatch, un encuentro de ‘citas rápidas’ organizado por BioIncubaTech y Bioga que potencia las oportunidades de negocio en el sector salud

by BioIncubaTech

Alrededor de 40 empresas y agentes del sector biotecnológico de Galicia, Cataluña, País Vasco, Asturias, Madrid, Aragón, Comunidad Valenciana y Portugal participaron ayer en Health BioMatch, un en...

Read more

New all-time investment record in the BioRegion, new investment funds, IPOs and unbridled acquisitions

by Biocat

Less than one month after the presentation of the 2021 BioRegion of Catalonia Report celebrating another year of record funding, SpliceBio closed one of the biggest rounds of funding in the life scien...

Read more

Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal

by Ysios Capital

After a very active 2021, closing an oversubscribed €216M fund, 3 NASDAQ IPOs, and Sanifit’s landmark acquisition by Vifor Pharma, Ysios Capital is now focused on managing its portfolio companies ...

Read more

Medibiofarma cierra nueva ronda de financiación por valor de 1,

by Palobiofarma

Medibiofarma ha cerrado una ronda de financiación de 1,2 millones de euros, con el apoyo financiero de su equipo promotor y otros socios de contrastada experiencia en el ámbito de la salud y la tecn...

Read more

Integra Therapeutics closes a new investment of €1.5M with the addition of Columbus Venture Partners to seed round

by Professional Newco

Integra Therapeutics, a biotechnology company that creates next generation gene writing tools, has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. T...

Read more

Sidekick, líder en terapias de salud digitales participada por Sabadell Asabys, cierra una Serie B de $55M para impulsar su crecimiento

by Asabys Partners

El líder global en terapias de salud digital Sidekick Health (www.sidekickhealth.com) anuncia hoy el cierre de una ronda de financiación Serie B de $55 millones. La ronda ha sido liderada por la fir...

Read more

Crowdfunding and Venture Capital: two complementary systems for private funding in the health sector

by GENESIS Biomed

As we already know, public funding is not enough to cover the entire life cycle of a company in the health sector. In fact, it is becoming increasingly common for public funding sources to contain in ...

Read more

ERC funds CRG ‘designer cytokine therapy’ project

by Centre for Genomic Regulation

Thanks to a new Proof of Concept Grant granted today by the European Research Council (ERC), CRG researchers led by Dr. Luis Serrano will explore new methods that improve the therapeutic effectiveness...

Read more

Minoryx raises €51 million in a round co-led by Columbus Venture Partners and Caixa Capital Risc to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

by Ysios Capital

The round was co-led by Columbus Venture Partners and Caixa Capital Risc. Dr. Damià Tormo, representing Columbus Venture Partners, has joined Minoryx’s Board of Directors. CDTI, through its Innvier...

Read more

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

by Ysios Capital

Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-H...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

A Vall d'Hebron study suggests the influ...

by Vall d’Hebron

It has been seen a relationship between consuming certain food groups ...

Photos Stream